GentiBio
Martina is a Senior Scientist on the Discovery Research team at GentiBio where she helps to uncover novel strategies to utilize Tregs for the treatment of autoimmune disorders. She is originally from Italy and got her Master’s degree in Molecular Biology from the University of Rome. She then moved to California for her graduate studies and earned her Ph.D. in Microbiology and Molecular Genetics from UC Irvine, focusing on Salmonella pathogenesis and mucosal immunology. Prior to joining GentiBio, she was a Cancer Irvington Research postdoctoral fellow in the Benoist & Mathis laboratory at Harvard Medical School. There, her research focused on microbial-induced intestinal Tregs.
GentiBio
GentiBio, Inc., is an early stage biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory and allergic diseases. GentiBio's proprietary autologous and allogeneic EngTregs platform integrates key complimentary technologies needed to successfully restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics. GentiBio is at the forefront of leveraging a unique therapeutic modality that can be used to address the fundamental cause of many diseases that result from overshooting and/or malfunctioning of the immune system.